MGP and atrial fibrillation: Furthermore, some drugs such as vitamin K antagonists used in patients with end-stage CKD and atrial fibrillation appear to be involved in VC, through mechanisms that include matrix Gla protein (MGP) inhibition and the γ-carboxylation of other proteins that regulate mineralization [7].